Inventiva’s 2020 Full-Year Financial Results Presentation
February 23 2021 - 4:00PM
Inventiva’s 2020 Full-Year Financial Results Presentation
Daix (France), February 23, 2021 –
Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage
biopharmaceutical company focused on the development of oral small
molecule therapies for the treatment of non-alcoholic
steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other
diseases with significant unmet medical need, today announced that
its management team will host a webcast to present the Company’s
full-year financial results for 2020 on Friday, March 5, 2021.
Inventiva’s 2020
full-year financial results will be released on Thursday, March 4,
2021 at 4:00 pm (New York), 10:00 pm (Paris).
Frédéric Cren, Chairman, CEO and cofounder of
Inventiva, Pierre Broqua, Chief Scientific Officer and cofounder of
Inventiva, Jean Volatier, Chief Financial Officer of Inventiva, and
Michael Cooreman, Chief Medical Officer of Inventiva, will hold a
conference call in English, followed by a Q&A
session, on Friday, March 5, 2021 at 8:00
am (New York), 2:00 pm (Paris).
The conference call and the slides of the
presentation will be webcast live at:
https://edge.media-server.com/mmc/p/wr8srgzq and also available on
Inventiva’s onwards in the “Investors” – “Financial results”
section.
To join the conference call, please use the code
3586531 after dialing one of the following
numbers:
France: +33 (0) 1 70 70 07 81Belgium: +32 (0) 2 793 3847Germany:
+49 (0) 69 2222 2625Netherlands: +31 (0) 20 795 6614Switzerland:
+41 (0) 44 580 7145United Kingdom: +44 (0) 207 192 8338United
States: +1 646-741-3167
Please note that the line will be opened 10 minutes before the
start of the conference call.
A replay of the conference call and the
presentation will be available after the event at:
http://inventivapharma.com/investors/financial-results-presentations/
About Inventiva
Inventiva is a clinical-stage biopharmaceutical
company focused on the development of oral small molecule therapies
for the treatment of NASH, MPS and other diseases with significant
unmet medical need.
Leveraging its expertise and experience in the
domain of compounds targeting nuclear receptors, transcription
factors and epigenetic modulation, Inventiva is currently advancing
two clinical candidates, as well as a deep pipeline of earlier
stage programs.
Lanifibranor, its lead product candidate, is
being developed for the treatment of patients with NASH, a common
and progressive chronic liver disease for which there are currently
no approved therapies. Inventiva recently announced positive
topline data from its Phase IIb clinical trial evaluating
lanifibranor for the treatment of patients with NASH and obtained
Breakthrough Therapy and Fast Track designation for lanifibranor in
the treatment of NASH.
Inventiva is also developing odiparcil, a second
clinical stage asset, for the treatment of patients with subtypes
of MPS, a group of rare genetic disorders. Inventiva announced
positive topline data from its Phase IIa clinical trial evaluating
odiparcil for the treatment of adult MPS VI patients at the end of
2019 and received FDA Fast Track designation in MPS VI for
odiparcil in October 2020.
In parallel, Inventiva is in the process of
selecting an oncology development candidate for its Hippo
signalling pathway program. Furthermore, the Company has
established a strategic collaboration with AbbVie in the area of
autoimmune diseases. AbbVie has started the clinical development of
ABBV‑157, a drug candidate for the treatment of moderate to severe
psoriasis resulting from its collaboration with Inventiva. This
collaboration enables Inventiva to receive milestone payments upon
the achievement of pre-clinical, clinical, regulatory and
commercial milestones, in addition to royalties on any approved
products resulting from the collaboration.
The Company has a scientific team of
approximately 70 people with deep expertise in the fields of
biology, medicinal and computational chemistry, pharmacokinetics
and pharmacology, as well as in clinical development. It also owns
an extensive library of approximately 240,000 pharmacologically
relevant molecules, approximately 60% of which are proprietary, as
well as a wholly‑owned research and development facility.
Inventiva is a public company listed on
compartment C of the regulated market of Euronext Paris (ticker:
IVA - ISIN: FR0013233012) and on the Nasdaq Global Market in the
United States (ticker: IVA). www.inventivapharma.com
Contacts
InventivaFrédéric CrenChairman &
CEOinfo@inventivapharma.com+33 3 80 44 75 00 |
Brunswick GroupYannick Tetzlaff / Tristan Roquet
Montegon / Aude LepreuxMedia
relationsinventiva@brunswickgroup.com+33 1 53 96 83 83 |
Westwicke,
an ICR CompanyPatricia L. Bank Investor
relationspatti.bank@westwicke.com+1 415 513-1284 |
- Inventiva - PR - Webcast invitation FY 2020 - 23 02 2021 -
EN
Inventiva (EU:IVA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Inventiva (EU:IVA)
Historical Stock Chart
From Jul 2023 to Jul 2024